Defective Hepatic Response to Interferon and Activation of Suppressor of Cytokine Signaling 3 in Chronic Hepatitis C by Huang, Ying et al.
Defective Hepatic Response to Interferon and Activation of
Suppressor of Cytokine Signaling 3 in Chronic Hepatitis C
YING HUANG*, JORDAN J. FELD*, RONDA K. SAPP*, SANTOSH NANDA*, JIING-HUEY
LIN‡, LAWRENCE M. BLATT‡, MICHAEL W. FRIED§, KRISHNA MURTHY||, and T. JAKE
LIANG*
*Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes
of Health, Bethesda, Maryland ‡InterMune, Inc, Brisbane, California §Division of Gastroenterology and
Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina ||Department of
Virology and Immunology, Southwest Foundation for Biomedical Research, San Antonio, Texas
Abstract
Background & Aims—Approximately half of hepatitis C virus (HCV)-infected patients do not
respond to current interferon (IFN)-α combination therapy. To understand IFN-α resistance in vivo,
we examined the dynamic responses to both type I and type II IFNs, human IFN (hIFN)- α, -γ, and
consensus IFN, in the chimpanzee model.
Methods—Naive and HCV-infected chimpanzees were treated with 3 forms of hIFNs in vivo.
Quantitative real-time polymerase chain reaction was performed to evaluate the expression of IFN-
stimulated genes (ISGs) in both peripheral blood mononuclear cells and liver to compare the
responses to hIFN between naive and infected chimpanzees. The hepatic expression of IFN signaling
components and inhibitory regulators including suppressor of cytokine signaling 3 (SOCS3) were
assessed. SOCS3 expression was also evaluated in the liver of HCV-infected patients undergoing
IFN treatment.
Results—The in vivo responses to all 3 hIFNs were much lower in the HCV-infected chimpanzees
than those in the naive chimpanzees. This defect was particularly evident in the liver because
induction of hepatic ISGs was barely detectable in the infected animals. Following IFN
administration, the expression of SOCS3 was significantly up-regulated, possibly through induction
of interleukin-6, in the liver of HCV-infected chimpanzees. HCV-infected humans also showed a
differential pattern of hepatic SOCS3 expression in response to IFN that is associated with treatment
response.
Conclusions—Our data indicate a predominantly defective hepatic response to IFN in HCV-
infected chimpanzees, which is probably mediated through the activation of SOCS3 and may explain
the nonresponse of many HCV patients to IFN-based therapy.
Hepatitis C virus (HCV) infection is one of the most common blood-borne chronic infections
with an estimated 170 million infected people worldwide. In the United States, approximately
3 million people are chronically infected, and HCV is the leading cause of liver transplantation.
1 No HCV vaccine is available to date, and the current antiviral therapy with pegylated
interferon (IFN)- α (Peg-IFN-α) and ribavirin is expensive, effective in approximately 50% of
patients, and associated with numerous adverse effects.2 Thus, there is a pressing need for
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improvement of anti-HCV therapy.3 To achieve this goal, it is crucial to understand the
mechanisms of HCV clearance and nonresponse to IFN-based therapy in HCV patients.
IFNs are naturally occurring proteins secreted by mammalian cells that play a critical role in
control of viral infection and provide a link between innate and adaptive immunity. There are
3 types of IFN: type I IFNs include the 14 nonallelic subtypes of IFN-α subtypes, as well as
IFN-β, -ε, -κ, -ω, and -τ, all of which bind to the type I IFN receptor (IFNAR); type II IFN,
IFN-γ, binds to the type II IFN receptor; type III IFNs include 3 recently discovered proteins
called IFN-γ that bind to a novel type III receptor.4 Consensus IFN-λ (IFN alfacon-1) is a
synthetic type I IFN, whose sequence is derived from the consensus sequences of various IFN-
α subtypes.5 It has been shown to be more potent than naturally occurring type I IFNs in cell
culture models and more effective in clinical trials for the treatment of chronic hepatitis C.6,7
IFN induces an antiviral state in cells by activating the Janus kinase (JAK)-signal transducers
and activators of transcription (STAT) pathway.8 Binding of IFN to its receptor activates
constitutively associated JAK proteins, which leads to the docking of STAT molecules to the
receptor and subsequent STAT phosphorylation. The activated STATs dissociate from the
receptor chain and form dimers that translocate to the nucleus to modulate gene transcriptional
activity. For the type I IFNs, the interferon-stimulated gene factor 3 (ISGF3) complex,
consisting of a STAT1 and STAT2 heterodimer and interferon regulatory factor 9 (IRF9), binds
to the interferon-stimulated response element (ISRE). For the type II IFN, IFN-γ, STAT1
homodimers bind directly to the γ-activated site element. Both types of IFNs induce the
expression of a large number of ISGs with substantial overlap and set up an antiviral,
antiproliferative, and immunoregulatory state in the host cells. IFN-induced antiviral activities
have been extensively studied in the HCV replicon system. Both IFN-α and IFN-γ have been
shown to inhibit HCV replication,9,10 and type I/II IFN combinations resulted in a synergistic
antiviral effect.11,12 However, standard combination therapy with Peg-IFN-α and ribavirin
achieves sustained viral clearance in only approximately half of treated patients, and IFN-γ as
a single agent appears to be ineffective in small clinical trials.13 HCV appears to have
developed strategies to interfere with the IFN effector pathways, leading to non-response in
many HCV-infected patients.
The mechanisms by which HCV interferes with IFN signaling and attenuates its antiviral
efficacy have not been fully elucidated. Various hypotheses have been proposed.14 Among
them, 2 negative regulators, suppressor of cytokine signaling (SOCS) 3 and protein inhibitor
of activated STAT (PIAS), have recently been reported to be induced by HCV proteins leading
to inhibition of the JAK-STAT signaling. SOCS3 can be induced by the HCV core protein and
suppress JAK-STAT signaling to block the IFN-induced formation of ISGF3 in cell culture.
15 HCV protein expression in liver cells is associated with activation of PIAS and inhibition
of STAT function, possibly augmented by induction of protein phosphatase 2A (PP2A)
expression.16
Despite significant advances in understanding of the actions of IFN in the cell culture system,
little is known about the inhibition of IFN signaling by HCV and nonresponse to IFN therapy
in vivo. The chimpanzee is the only animal model susceptible to HCV infection. In the present
study, we conducted a comprehensive assessment of the antiviral effects of both type I and
type II IFNs (IFN-α, -γ, and consensus IFN) in chimpanzees and demonstrated a potential
mechanism of IFN resistance. To confirm the clinical relevance in human HCV infection, we
also evaluated patient samples before and during Peg-IFN therapy.
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Six chimpanzees, X0176, X0284, X0101, X0233, X0142, and X0234, were maintained at the
Southwest Foundation for Biomedical Research, an Association for Assessment and
Accreditation of Laboratory Animal and Care-accredited facility, and the study protocol was
approved by the Institutional Animal Care and Use Committee at the Foundation and by the
Interagency Animal Model Committee at the National Institutes of Health (NIH). Two
chimpanzees, X0142 and X0234, had persistent infection with HCV genotype 1b derived from
a homogenous source as described previously,17 whereas others were naive animals. Whole
blood samples from 2 chimpanzees, X6394 and X6475 (infected with genotype 1a viruses),
18,19 were provided by Dr. Stephen Feinstone at Center for Biologics Evaluation and Research
(CBER), the Food and Drug Administration (FDA).
Human IFN-α2a used for the in vitro study was purchased from Fitzgerald Industries
International, Inc. (Concord, MA), and the product used for in vivo study was purchased from
Roche (Nutley, NJ). IFN-γ1b and consensus IFN (Infergen, IFN alfacon-1) were provided by
InterMune, Inc. (Brisbane, CA).
Patient Samples
Patient samples were derived from 2 sources. Treated patients were recruited from the Liver
Diseases Unit at the University of North Carolina (UNC). Patients were given an initial dose
of 180 μg Peg-IFN-α-2a and underwent liver biopsy 24 hours later. Control samples came from
liver biopsy specimens obtained from patients at the Clinical Center of the NIH prior to
undergoing antiviral therapy with Peg-IFN and ribavirin. Control patients were selected to
match treated patients in terms of age, gender, ethnicity, initial viral load, and degree of
histologic disease. Patients signed informed consent, and the protocol was approved by the
Institutional Review Board of UNC and the NIH. All patients had genotype 1 HCV infection.
Biopsy samples were snap frozen in liquid nitrogen and stored at −80°C. Details of the human
study will be published elsewhere.20 Human liver biopsy tissue was handled similarly to
chimpanzee liver tissue as described below. Both treated and control patients subsequently
underwent a full course of standard antiviral therapy consisting of Peg-IFN-α-2a 180 μg and
weight-based ribavirin (1000 mg daily ≤75 kg and 1200 mg >75 kg for 48 weeks). Patients
achieving ≥2-log copies/mL decrease in HCV RNA by 4 weeks of therapy were deemed rapid
responders (RR), and those with lesser decreases in viral load were designated slow responders
(SR).
Peripheral Blood Mononuclear Cells Isolation and IFN Stimulation
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood samples of
chimpanzees and healthy human donors (informed consents were obtained) and stimulated
with 3 different doses of human IFN (hIFN)-α, -γ, and consensus IFN in RPMI medium with
10% fetal bovine serum (FBS) (Cellgro, Herndon, VA). After incubation for 6 or 24 hours,
cells were harvested and subjected to RNA isolation.
Chimpanzee Experiment
Chimpanzees used for in vivo study were treated sequentially with 10 million IU IFN-α, 400
μg IFN-γ, and 30 μg consensus IFN subcutaneously. Briefly, 4 animals (X0101, X0233, X0142,
and X0234) were divided into 2 groups, each comprising 1 naive and 1 infected chimpanzee.
The experiment was separated into 3 phases. For the first phase, group 1 chimpanzees (X0101
and X0142) were administered with IFN-α and group 2 (X0233 and X0234) with IFN-γ. Blood
samples (40 mL each) were collected at 9 time points (pretreatment, 8 hours, 24 hours, 48
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hours, 72 hours, 7 days, 14 days, 21 days, and 28 days posttreatment), and liver biopsy samples
were collected at 5 time points (pretreatment, 8 hours, 24 hours, 48 hours, and 72 hours
posttreatment). All animals were rested for 6 weeks to avoid any residual drug effect. Next,
group 1 was treated with IFN-γ and group 2 with IFN-α for the second phase of the study.
Similar sample-collecting procedures were performed during treatment up to 4 weeks. The
animals were rested for 6 weeks and started on the third and final phase of the study, in which
consensus IFN was given to both groups. Because of a nonspecific infection during the rest
period after the phase II study, one of the HCV-infected chimpanzees, X0142, was dropped
from the phase III study.
Quantification of Serum HCV RNA and Alanine Transaminase
Sera were isolated from serial blood samples of the HCV-infected chimpanzees. HCV RNA
was quantified by using the COBAS AMPLICOR HCV MONITOR TEST, v2.0 (Roche
Diagnostics, Branchburg, NJ), which has a detection limit of 600 IU/mL (1620 copies/mL).
Alanine transaminase (ALT) values were measured by the Laboratory Medicine Department
of the Southwest Foundation for Biomedical Research.
TaqMan Real-Time PCR Analysis
Total RNA was prepared from the PBMCs and liver biopsy tissues with RNeasy Mini Kit
according to manufacturer’s instructions (Qiagen, Valencia, CA). Complementary DNA
(cDNA) was synthesized from total RNA with First-strand cDNA Synthesis System (Marligen
Biosciences, Ijamsville, MD). TaqMan real-time PCR analysis was used to quantify the mRNA
expression levels of genes of interest. The primers and probes used were Gene Expression
Assays (Applied Biosystems, Foster City, CA). Each reaction was performed in duplicate, and
all samples were standardized using the internal control glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) gene. Reactions were set up using 12.5 μL TaqMan universal PCR
master mix, cDNA template, and 1.25 μL primers and probe mix in a final volume of 25 μL.
Reactions were performed on an iCycler iQ Multicolor Real-Time Detection System (Bio-Rad,
Hercules, CA) with the following reaction conditions: 95°C for 10 minutes, followed by 40
cycles of 95°C for 20 seconds, 60°C for 1 minute, and additional incubation at 68°C for 10
minutes.
Western Blot Analysis
Liver biopsy tissues were lysed using mammalian tissue lysis/extraction reagent (CelLytic MT;
Sigma Chemical Co., St. Louis, MO) containing a Protease Inhibitor Cocktail Tablet (Roche,
Indianapolis, IN) and a Protein Phosphatase Inhibitor Set (Upstate Biotechnology, Lake Placid,
NY). The collection of supernatant lysates, determination of protein concentration, and
Western blot analysis have been described previously.21 Antibodies to STAT1, SOCS1,
SOCS3, Src homology region 2-domain phosphatase (SHP)1, and β-actin were from Abcam
Inc. (Cambridge, MA). Antibodies to STAT2, STAT3, phosphorylated STAT1 (Y701), and
protein phosphatase 2A C subunit (PP2Ac) were from Upstate Biotechnology. Anti-IRF9
antibody was from Santa Cruz Biotechnology (Santa Cruz, CA), and anti-IFNAR chain 2
antibody was from Fitzgerald Industries International Inc. (Concord, MA). The band intensities
in the images were quantified by a public analysis program, ImageJ, offered by the NIH
(http://rsb.info.nih.gov/ij/).
Serum Cytokine Analysis
Serum cytokines (eotaxin, GM-CSF, IFN-γ, interleukin (IL)-1α, IL-1β, IL-2, IL-3, IL-4, IL-5,
IL-6, IL-7, IL-8, IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, interferon-γ-inducible protein
(IP) 10, membrane cofactor protein (MCP)-1, macrophage inflammatory protein (MIP)-1α,
tumor necrosis factor (TNF)-α, and RANTES) were measured simultaneously using Beadlyte
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Human 22-Plex Cytokine Detection System (Upstate Biotechnology) according to the
manufacturer’s instructions. Briefly, both standard and chimpanzee samples were diluted with
human serum diluent, and 50 μL was loaded onto the 96-well filtration plate. Twenty-five-
microliter beads coated with target capture antibodies against cytokines were added to each
well and incubated overnight at 4°C with low-speed shaking at 300 rpm in the dark. On the
next day, after washing, the plate was supplied with 25 μL premixed biotin conjugate antibodies
and incubated for 2 hours at room temperature with shaking at 300 rpm. Finally, streptavidin-
phycoerythrin was added, and the results were read with Bioplex Luminex System (Bio-Rad
Laboratories Inc., Hercules, CA). The data were analyzed using Bio-Plex Manager software
v.4.0 with Five-Parameter Logistics curve fitting.
Results
Response of Chimpanzees to hIFNs In Vitro
Before performing the in vivo chimpanzee study, we first determined the ability of chimpanzees
to respond to hIFN. PBMCs from 2 naive chimpanzees (X0284 and X0176) and 2 healthy
human donors were stimulated with 3 different doses of IFN-α, IFN-γ, and consensus IFN. A
panel of previously reported IFN-α or -γ specific ISGs were selected for analysis: myxovirus
resistance 1 (MX1), 2,5-oligoadenylate synthetase (2,5-OAS), IFN-induced protein with
tetratricopeptide repeats 1 (IFIT1), and IFN-induced protein 15 (IFI15) were used as markers
of IFN-α-induced genes, and the IP10, IRF1, and large multifunctional protease (LMP) 2 and
LMP7 were selected as IFN-γ-induced genes.22 All ISGs were induced at 6 hours after IFN
treatment (data not shown) and reached a peak at 24 hours (Figure 1). The overall gene
expression patterns of the ISGs were comparable between human and chimpanzee PBMCs.
Consensus IFN was more potent and induced a broader range of ISGs than either IFN-α or -
γ. All 3 IFNs induced higher levels of ISG expression in humans than in chimpanzees (2–5
times higher), suggesting that chimpanzees do not respond as well as humans to hIFN in vitro.
Based on these data, 10 million IU IFN-α, 400 μg IFN-γ, and 30 μg consensus IFNs were used
for in vivo study in chimpanzees. These doses are 3– 4 times higher than the standard doses
for the treatment of human subjects (3 million IU IFN-α, 100 μg IFN-γ, and 9 μg consensus
IFN) to compensate for the lower efficacy of hIFNs in chimpanzees.
Impaired Response of HCV-Infected Chimpanzees to hIFN In Vivo
Four chimpanzees (2 naive: X0101 and X0233; 2 infected: X0142 and X0234) were divided
into 2 groups in the in vivo study. Each group consisted of 1 naive and 1 infected animal. The
experiment was divided into 3 phases: treatment with IFN-α (or IFN-γ), treatment with IFN-
γ (or IFN-α), and treatment with consensus IFN, respectively. With this design, each animal
received all 3 forms of IFN treatment, which allows for internal control and biologic duplication
of the experiment. Consensus IFN was given last because consensus IFN is more potent and
induces a broader range of ISGs than either IFN-α or -γ. Similar to the results from the in vitro
study, IFN-α and consensus IFN treatment led to the induction of the IFN-α-specific ISGs
(MX1, OAS1, IFIT1, and IFI15) in both PBMCs and liver tissues of the chimpanzees in vivo.
Likewise, the IFN-γ-specific ISGs (IP10, IRF1, LMP2, and LMP7) were induced by IFN-γ and
consensus IFN in vivo. Figure 2 shows the fold inductions of only 4 selected ISGs (MX1,
IFI15, IP10, and IRF1), but the other 4 (IFIT1, OAS1, LMP2, and LMP7) behaved similarly.
Although PBMCs from both naive and HCV-infected chimpanzees responded to all 3 forms
of IFN, reaching a peak at 8 hours posttreatment and returning to basal levels within 48 hours,
the levels of ISG induction in PBMCs from HCV-infected chimpanzees were much lower (~4
times) than those in the naive animals (Figure 2A). All 3 forms of IFN induced stronger ISG
responses in the liver than in PBMCs of naive chimpanzees (Figure 2B). However, in the HCV-
infected animals, little or no hepatic ISG induction was observed. Although hepatic ISG
induction was severely blunted in the infected animals, the basal level of ISG expression in the
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liver were higher than those in naive animals (Figure 2C), suggesting that HCV infection
resulted in endogenous IFN production. The higher basal hepatic ISG expression did not
account for the failure to respond to exogenous IFN because the absolute levels reached after
treatment were still much lower in infected than naive chimpanzees (Figure 2D). These data
indicate a deficiency of response, particularly in the liver, to hIFNs in HCV-infected
chimpanzees.
Effect of IFN on Viral Level of HCV-Infected Chimpanzees
HCV RNA and ALT levels were analyzed from serial serum samples of the 2 chronically HCV-
infected chimpanzees (X0142 and X0234) pre- and post-IFN administration. As shown in
Figure 3, although chimpanzee X0234 was initially inoculated with the week 2 serum from
X0142 (ie, the same viral strain),17 the pattern of infection that ensued differed somewhat
between the 2 chimpanzees. The viral load was much higher in X0142 and fluctuated in a range
from 104 to 106 copies/mL as compared with a relatively stable viremia (approximately 3 ×
104 copies/mL) seen in X0234. Notably, neither IFN-α nor IFN-γ injection resulted in a
significant decrease in viral load in either chimpanzee, consistent with the absence of hepatic
ISG induction in both animals. However, chimpanzee X0234 did have a transient decrease in
viremia in response to IFNs with a reproducible decrease in viral titer of 0.5–1 log copies/mL
(IFN-γ < IFN-α < conIFN) at 8–24 hours posttreatment. Interestingly, although the hepatic IFN
response in this chimpanzee was blunted compared with naive animals, there was low-level
induction of hepatic ISGs in response to IFNs (eg, MX1 and IFI15 induced by IFN-α; IP10
and IRF1 induced by IFN-γ, Figure 2B and 2D). In contrast, chimpanzee X0142 had no hepatic
ISG induction after treatment and actually had a transient increase in HCV viremia within 24–
48 hours posttreatment, which appeared to coincide with a transient ALT increase in this
chimpanzee (data not shown). This effect could be explained by an IFN-induced hepatotoxicity
with release of HCV RNA from the injured hepatocytes resulting in a transient rise in viremia.
Comparable Induction of ISGs in PBMCs From Infected and Naive Chimpanzees Ex Vivo
Because of the apparently different ISG induction in PBMCs between the naive and infected
chimpanzees in vivo, we sought to determine whether such a difference persists ex vivo, free
of any potential biologic interactions with IFN that may be operational in vivo. Thus, we
evaluated the actions of IFNs on PBMCs isolated from naive and infected chimpanzees in vitro.
Eight chimpanzees, 4 naive and 4 HCV infected, were studied. The 4 naive animals included
the 2 used in the preliminary study to test the response of chimpanzees to hIFNs (X0176 and
X0284) and 2 others used in the in vivo study above (X0101 and X0233). The 4 infected animals
were the 2 used for the study above (X0142 and X0234) and 2 others infected with a genotype
1a strain H77 (X6394 and X6475).18,19 Figure 4 summarizes the fold inductions of
representative ISGs in PBMCs from all 8 chimpanzees at 24 hours post-IFN stimulation. The
overall ISG inductions of the HCV-infected animals were comparable with those of the naive
animals with the exception of IP10, whose induction by IFN-γ was significantly lower in the
infected chimpanzees. However, the difference in IP10 induction of PBMCs by IFN-γ between
naive and infected chimpanzees ex vivo was much less than that in vivo (2-to 3-fold vs 4- to
6-fold, respectively). These data suggest that the apparent difference in IFN response occurred
mostly in vivo, and, once the PBMCs were removed from the in vivo milieu of the infected
animals, they responded to IFN similarly to those from the naive animals.
Persistent Activation of the JAK-STAT Pathway in the Liver of HCV-Infected Chimpanzees
The lack of hepatic ISG induction after IFN treatment in HCV-infected chimpanzees suggests
that the IFN signal transduction pathways are inhibited in the liver. To determine which step
of IFN signaling was inhibited, various components involved in the JAK-STAT pathway were
evaluated using Western blot analysis from liver biopsy samples of pre- and 8 hours post-IFN-
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α treatment. The 8-hour time point was chosen to coincide with the peak hepatic ISG expression
(Figure 2B). As shown in Figure 5A for the naive chimpanzees, a slight increase of
phosphorylated STAT1 was detected with X0101, whereas not with X0233. In these
chimpanzees, the JAK-STAT pathway was likely activated by exogenous IFN but quickly
returned to baseline by 8 hours. This time course is consistent with the rapid onset and transient
nature of JAK-STAT activation by IFN observed in vitro.23 In contrast, all components of the
JAK-STAT pathway were activated even prior to IFN treatment in the infected chimpanzees.
In addition to a markedly elevated level of phosphorylated STAT1, there was a general increase
seen in the total levels of STAT1, STAT2, STAT3, and IRF9 proteins (Figure 5A). This effect
was more dramatic in chimpanzee X0142. After IFN treatment, rather than increasing, the
phosphorylated STAT1 level actually declined in X0142, which might be due to the activation
of negative regulator(s) of IFN signaling. This observation is in keeping with the lack of ISG
induction in the liver of these infected animals.
Enhanced Hepatic SOCS3 Expression in Response to IFN in HCV-Infected Chimpanzees
At least 3 different classes of negative regulators are known to contribute to the inhibition of
IFN signaling24: the SHP1, SOCS, and PIAS families. To explore whether these suppressors
were responsible for the IFN resistance seen in the HCV-infected chimpanzees, we measured
the expression levels of regulatory factors SHP1, SOCS1, SOCS3, and PP2A in liver biopsy
samples pre- and post-IFN-α induction (Figure 5A). Among these factors, the SOCS3 protein
level increased significantly in HCV-infected but not in naive animals after IFN treatment.
This increase was also confirmed at the RNA level by quantitative real-time PCR (Figure
5B). Although the hepatic SOCS3 mRNA level also increased modestly in naive animals, the
increase was much more dramatic in HCV-infected animals (X0142 > X0234). These data
indicate that the SOCS3 up-regulation may be a potential mechanism for the defective IFN
response in HCV-infected chimpanzees.
Induction of IL-6 by IFN in Serum and Liver Tissue of HCV-Infected Chimpanzees
Because SOCS3 can be induced by a variety of cytokines including the proinflammatory
cytokine IL-6, we determined the serum IL-6 levels following IFN administration in these
chimpanzees. Although the serum IL-6 levels increased in response to IFN in all chimpanzees,
the infected chimpanzee X0142 showed a more exaggerated augmentation (Figure 6A). A
similar pattern was confirmed by real-time PCR of IL-6 mRNA in the liver. This observation
is consistent with the high level of hepatic SOCS3 induction in chimpanzee X0142. In addition
to IL-6, we also evaluated a panel of cytokine/chemokine levels in sera of HCV-infected
chimpanzees compared with those of naive animals in response to IFN treatment. Among the
22 cytokines/chemokines measured, IP10, MCP-1, MIP-1α, and eotaxin were induced by both
type I and type II IFNs and behaved in a pattern similar to the ISG mRNA expression (Figure
6B).
Hepatic SOCS3 Expression in HCV-Infected Patients Pre- and Post-IFN Treatment
Based on the findings in chimpanzees, we evaluated SOCS3 mRNA expression in HCV-
infected patients pre- and post-IFN treatment. Two groups of genotype 1 virus infected-patients
were studied: a control group of 21 patients in whom liver biopsies were performed prior to
antiviral therapy and a treatment group of 13 patients in whom liver biopsies were performed
24 hours after an initial dose of Peg-IFN-α2a. Two groups were matched for age, gender, and
race. All control patients were subsequently treated, and their response to therapy is known.
Patients were categorized as rapid responders (RR) or slow responders (SR) depending on
whether they achieved a 2-log copies/mL drop in HCV viral titer by 4 weeks of therapy. This
early virologic response has been shown to be an accurate predictor of clinical treatment
response25 and probably a better marker of the antiviral effect of IFN in vivo because clinical
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end point is frequently altered by other clinical issues like noncompliance or adverse effects.
SOCS3 mRNA expression was evaluated by real-time PCR for all patient samples (Figure 7).
The treatment group had generally lower mean SOCS3 expression than the control patients
(Figure 7A). In the control group, patients who were considered as RR when treated later had
a higher SOCS3 expression than those as SR, whereas the SOCS3 expression was similar
between RR and SR among the treated patients. In light of the inverse trend, the relative change
in the RR and SR groups may be more biologically relevant. The fold change of hepatic SOCS3
in response to IFN is determined by taking the control group values as the baseline expression
levels for the treatment group according to their treatment response (Figure 7B). Although the
SR in the treatment group had a 1.7-fold higher absolute mean SOCS3 expression than that of
RR, they had a much less relative change than the RR (22.6-fold vs 268-fold; P = .037).
Discussion
Although new therapies based on small molecule inhibitors of HCV protease and polymerase
look promising for HCV infection, it is likely that they will be used in combination with, rather
than instead of, IFN-α-based regimens. Therefore, an improved understanding of the
mechanisms of action and resistance to IFN in HCV infection will be critical to improve
outcomes as well as for the development of new therapeutic approaches. In this study, we have
performed an extensive examination of the responses to 3 different forms of IFN in the PBMCs
and liver of the chimpanzee, which is the only reliable animal model of HCV infection. We
showed that, although less responsive than humans to hIFN, chimpanzees are able to respond
to hIFN-α, -γ, and consensus IFN in both PBMCs and liver. The patterns of ISG induction in
response to the various IFNs were similar to those previously reported in cell culture,22
chimpanzees,26,27 and humans.12 Although consensus IFN is derived from type I IFNs, it has
been shown to induce both type I- and type II-specific ISGs and was shown to be more potent
than either IFN-α or -γ in ISG induction. This effect is a result of the higher binding affinity
of consensus IFN to IFNAR than IFN-α5,28 and the cross interaction of the signal transduction
pathways between the 2 types of IFNs.
Our data are consistent with the recently reported microarray data showing strong ISG
induction after IFN-α treatment of naive chimpanzees.29 More importantly, for the first time,
we showed that HCV-infected chimpanzees had a blunted response to IFN therapy. Although
a lower ISG induction by all 3 forms of IFN was observed in PBMCs, the most notable
difference was seen in the liver. Despite high doses of all 3 forms of IFN, little or no hepatic
ISG induction was seen in the infected animals. Consistent with the lack of detectable IFN
response, there was little or no change in HCV viral load. The basal levels of ISG and
phosphorylated STAT1 expression were higher in infected than naive chimpanzees, indicating
that HCV infection led to a type I IFN response. This observation is consistent with previous
studies in chimpanzees26,27 and humans30,31 and raises the possibility that the ISGs were
already maximally induced in infected chimpanzees such that exogenous IFNs did not lead to
any further ISG induction. However, the increased basal level in the infected chimpanzees does
not account entirely for the reduced ISG induction because the absolute levels of ISGs after
IFN treatment were substantially lower in infected animals than those in naive animals (10- to
100-fold lower). This suggests that, in infected chimpanzees, there is interference with ability
to respond to IFN. Two possibilities could explain this blunted IFN response. During chronic
infection, the continuous but ineffective IFN action leads to a relatively resistant state of the
liver to further exposure of IFN. Continuous IFN action could lead to IFN receptor down-
regulation, a phenomenon indeed observed in ligand-receptor interaction. We found no
decrease in IFNAR in either chimpanzees or humans (data not shown) before or during IFN
treatment, consistent with previous in vitro data.32 Alternatively, chronic HCV infection, either
through a direct viral mechanism or indirect actions, may activate negative regulator(s) of IFN
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leading to an IFN resistant state in the liver. This concept is supported by the observation that
chronic hepatitis C patients may be more susceptible to other hepatic viral infections.33,34
The observation that hepatic phosphorylated STAT1 showed a paradoxical decline after IFN
treatment in the infected animals strongly supports the activation of an IFN-inhibitory pathway,
as postulated above. By assessing the status of the various IFN-signaling inhibitors in the liver
biopsy samples, we found that, following IFN administration, the expression of SOCS3 was
significantly up-regulated. It appears that the induction of SOCS3 expression was much more
dramatic at the mRNA (Figure 5B) than the protein level (Figure 5A) for both infected
chimpanzees. This difference might be due to the unstable nature of the SOCS proteins and
the lack of samples at earlier time points, which made it difficult to compare the 2 levels.
SOCS3 acts by interacting with the JAKs, resulting in impaired STAT1 and STAT3
phosphorylation. This leads to reduced STAT1 nuclear translocation, lack of binding to the
ISRE, and ultimately decreased ISG expression.24 Being IFN inducible, SOCS3 expression
is also induced by IL-6, IL-10, TNF-α, and toll-like receptors 4 and 9.35 A previous study
using an HCV transgenic mouse model showed a similar inhibition of JAK-STAT signaling
by HCV expression; however, no induction of SOCS1 or SOCS3 was detected.36 On the other
hand, HCV core protein has been shown to induce SOCS3 expression in several cell lines,
resulting in impaired IFN and specifically STAT1 signaling.15,37,38 In addition, Zhu et
al32 also showed that cells harboring HCV replicons resistant to IFN therapy produced higher
levels of SOCS3. With silencing of SOCS3, IFN sensitivity was partially restored.32 Our in
vivo finding of increased SOCS3 expression and reduced phosphorylated STAT1 after IFN
treatment is consistent with the known functional mechanism of this IFN-inhibitory pathway.
This pathway could provide a plausible explanation for a direct viral mechanism of IFN
resistance in vivo.
If SOCS3 expression were induced by viral proteins, only infected cells would be resistant to
IFN. However, our in vivo data suggest a general IFN-resistant state in the infected liver (Figure
2B). Alternatively, activation of IFN inhibitory pathway(s) may occur through the production
of soluble factor(s) that act in an autocrine/paracrine fashion in the liver and to a lesser extent
PBMCs as they traverse the liver in blood. To examine the possible soluble factor(s), we studied
a panel of cytokine/chemokine levels in the serum of HCV-infected and naive chimpanzees in
response to IFN treatment. Several cytokines have been reported to be induced by HCV
proteins, such as IL-6, IL-8, TNF-α, MCP-1, and RANTES.39–43 Among them, IL-8 has been
shown to have anti-IFN activity through inhibition of ISGF3 assembly and interaction with the
ISRE. We found no induction of IL-8 by IFN in infected chimpanzees. However, IL-6 was
induced in response to IFN in both serum and liver tissue of the infected chimpanzees with a
time course similar to SOCS3 induction. Other cytokines known to modulate SOCS3
expression, such as IL-10 and TNF-α, were not induced by IFN in the infected animals. IL-6
mRNA was not detectable in the livers of treated patients in our cohort; however, biopsies were
performed 24 hours after IFN treatment compared with 8 hours in the chimpanzees, and,
consequently, IL-6 expression may have been missed, particularly given the low levels seen
in chimpanzees suggesting that the peak may already have been missed at 8 hours.
Chen et al reported that human nonresponsders to IFN-α-based therapy had a higher expression
of numerous ISGs in pretreatment liver biopsy samples as compared with those who achieved
a sustained virologic response.44 The opposite pattern was seen with the hepatic SOCS3
expression in our cohort, with ~11-fold higher expression in control patients who responded
to treatment (RR group) compared with the nonresponders (SR group). As a negative regulator
of IFN, high SOCS3 levels prior to treatment would block ISG expression. With IFN-α
treatment, SOCS3 declines, allowing for ISG induction. The degree of ISG induction may be
more important than the absolute level of ISG expression for viral clearance. Consequently,
the baseline level of SOCS3 expression and the degree to which SOCS3 changes after IFN
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treatment determine the pretreatment level of ISG expression and the degree to which ISGs
can be induced by IFN-α therapy. In our human study, the SOCS3 expression declined much
less in the SR than the RR in response to IFN-α. This difference could contribute to a blunted
ISG induction in the human nonresponders. Infected chimpanzees, perhaps as an extreme
example of the human nonresponders, actually have a rise in hepatic SOCS3 with IFN therapy
and therefore exhibit little or no ISG induction and thus no decline in viremia.
Based on these observations, we propose a model (Figure 8) in which HCV infection leads to
endogenous IFN production and also to an increased expression of SOCS3, either directly by
a viral mechanism or indirectly by the induction of a soluble factor, possibly IL-6. As a
consequence of SOCS3 induction and other mechanisms (eg, interaction of HCV NS5A or E2
protein with double-strand RNA-dependent protein kinase [PKR]), the antiviral activity of IFN
is impaired, allowing HCV to establish persistent infection. In chimpanzees, IFN treatment
leads to further SOCS3 induction, which prevents ISG activation and markedly blunts the IFN
response. As described above in humans, SOCS3 declines but much greater in RR than in SR
after IFN treatment. This proposed inhibitory pathway is variably operational in HCV-infected
humans because of the genetic heterogeneity in the human population, thus accounting for the
diverse infection outcomes and treatment responses.
In summary, we have shown that chimpanzees respond to hIFNs with ISG production in both
PBMCs and liver. HCV infection leads to the production of type I IFN resulting in sustained
activation of the JAK-STAT pathway and ISG induction in the liver. Typical ISG responses
were seen in treated naive chimpanzees; however, ISG production was reduced in PBMCs and
almost completely abrogated in the liver of HCV-infected animals. SOCS3 expression was
markedly increased in the livers of infected chimpanzees after IFN treatment and was
associated with a decrease in phosphorylated STAT1. A similar pattern of SOCS3 expression
was seen in patients associated with treatment response. This negative regulator of IFN,
possibly mediated by the production of IL-6, may be an important mechanism of IFN
nonresponse in chronic HCV infection. Further studies to elucidate the biologic importance of
this interaction may have crucial implications for the improvement of current HCV therapy.
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ISG induction of chimpanzee PBMCs to human IFNs in vitro. PBMCs from naive chimpanzees
(X0284 and X0176) and healthy human donors (donors 1 and 2) were isolated and stimulated
with 3 forms of IFN. (A) IFN-α (10, 100, and 1000 U/mL); (B) IFN-γ (1, 10, and 100 ng/mL);
(C) consensus IFN (0.3, 3, and 30 ng/mL). Fold inductions of selected ISG mRNAs were
measured by real-time PCR at 24 hours posttreatment. Error bars indicate mean ± SD of 3
experiments. conIFN, consensus IFN.
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Baseline and induction of ISG in naive and HCV-infected chimpanzees in vivo. Induction of
ISG expression in PBMC (A) and liver (B) from naive (X0101 and X0233) and HCV-infected
(X0142 and X0234) chimpanzees in vivo. conIFN, consensus IFN. (C) Basal ISG expression
in the liver of all animals. The basal ISG levels, after normalized to GAPDH, were adjusted
by setting the value of naive chimpanzee (X0101) as 1 for each ISG. (D) The hepatic expression
levels of selected ISGs (MX1 and OAS1) in selected animals (X0233 and X0234) following
IFN administration (RU; relative unit, defined as copy number normalized to GAPDH).
HUANG et al. Page 16














Serum HCV RNA titers of HCV-infected chimpanzees in response to IFN. HCV RNA levels
of HCV-infected chimpanzees X0142 (A) and X0234 (B) were monitored for more than 1 year
prior to this study. Arrows indicate time points of IFN administration. conIFN, consensus IFN.
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ISG induction of PBMCs from naive and HCV-infected chimpanzees ex vivo. PBMCs from
naive (X0176, X0284, X0101, and X0233) and HCV-infected (X0142, X0234, X6394, and
X6475) chimpanzees were isolated and stimulated with IFN-α (10, 100, and 1000 U/mL) (A)
and IFN-γ (1, 10, and 100 ng/mL) (B), respectively. Fold inductions of selected ISG mRNAs
were measured by real-time PCR at 24 hours posttreatment and compared between naive and
infected groups. Error bars indicate mean ± SD for the 4 animals in each group. Inf, infected.
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Expression of IFN signaling molecules and inhibitory regulators in the liver of chimpanzees.
(A) Fifteen micrograms protein extracts of liver from chimpanzees with or without IFN-α
treatment (8 hours) were subjected to Western blot analysis with indicated antibodies. β-actin
was used as loading control. Band intensities were quantified with NIH ImageJ software. The
relative values for each protein are shown below the bands with the baseline value of naive
chimpanzee (X0101) setting as 100. (B) Liver SOCS3 mRNA expression levels measured by
real-time PCR (RU; relative unit, defined as copy number normalized to GAPDH).
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Induction of IL-6 by IFN in the serum and liver of HCV-infected chimpanzees. (A) Serum
protein and liver mRNA levels (RU; relative unit, defined as copy number normalized to
GAPDH) of IL-6 were determined. The detection limit of IL-6 mRNA level is 5 RU (dotted
line) in this assay. (B) A panel of serum cytokines was measured. Selected cytokines (IP10,
MIP-1α, MCP-1, and eotaxin) induced by IFN-α are shown.
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SOCS3 expression in human liver biopsy specimens pre-and post-IFN treatment. (A) The mean
SOCS3 expression (RU; relative unit, defined as copy number normalized to GAPDH) is shown
for the 2 subgroups of both treatment (t) and control (c) groups as described in the Materials
and Methods section, respectively. RR, rapid responder; SR, slow responder. (B) Fold change
in SOCS3 expression is calculated by dividing the mean SOCS3 expression of RR or SR in
the control group (c) by that of RR or SR in the treatment group (t), respectively; the fold
change is then shown as a negative value to account for the fact that SOCS3 expression declined
with treatment. Error bars are shown as mean ± SD.
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Model of IFN resistance in chronic HCV infection. HCV infection leads to endogenous IFN
production and also to increased expression of SOCS3, either directly by a viral protein (eg,
core) or indirectly by an IFN inhibitory factor (eg, IL-6 or other soluble factors). SOCS3 can
suppress JAK-STAT signaling by blocking the IFN-induced formation of ISGF3, therefore
allowing HCV to establish persistent infection. With exogenous IFN treatment, SOCS3 is
induced, preventing further ISG activation and markedly blunting the IFN response.
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